Exelixis’ oral tyrosine kinase inhibitor (TKI) was tied to a 20% reduced risk of death from colorectal cancer, appearing to ...

Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...

Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German ...

Sophia Genetics has launched an artificial-intelligence-powered tool that creates virtual copies of patients, known as ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...